Development and validation of high-throughput liquid chromatography–tandem mass spectrometric method for simultaneous quantification of Clopidogrel and its metabolite in human plasma
- 1 February 2010
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 878 (3-4), 502-508
- https://doi.org/10.1016/j.jchromb.2009.12.026
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic studyBiomedical Chromatography, 2007
- The validation of a bioanalytical method for the determination of clopidogrel in human plasmaJournal of Chromatography B, 2007
- Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic studyBiomedical Chromatography, 2006
- Determination of clopidogrel metabolite (SR26334) in human plasma by LC–MSJournal of Pharmaceutical and Biomedical Analysis, 2006
- Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2006
- Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic studyJournal of Chromatography B, 2005
- P2Y12, a New Platelet ADP Receptor, Target of ClopidogrelBiochemical and Biophysical Research Communications, 2001
- The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 2000
- Identification and Biological Activity of the Active Metabolite of ClopidogrelThrombosis and Haemostasis, 2000
- Clopidogrel HydrogensulfateDrugs of the Future, 1993